Free shipping above 75,00€ For domestic delivery

Novel Medicinal Mushroom Blend as a Promising Supplement in Integrative Oncology: A Multi-Tiered Study using 4T1 Triple-Negative Mouse Breast Cancer Model

Studies
Author/s: Asst.Prof. Andrej Gregori, PhD, Elisa Roda, Fabrizio De Luca, Carmine Di lorio, Daniela Ratto, Stella Siciliani, Beatrice Ferrari, Filippo Cobelli, Giuseppina Borsci, Erica Cecilia Priori, Silvia Chinosi, Andrea Ronchi, Renato Franco, Raffaele Di Francia, Massimiliano Berretta, Carlo Alessandro Locatelli, Elena Savino, Maria Grazia Bottone, Paola Rossi
Publish date: 13.05.2026

Breast cancer (BC) is the most frequent cancer among women, impacting 2.1 million women each year, also causing the greatest number of cancer-related deaths.

A great deal of progress has been made in the early detection and treatment of BC; thus, the survival has steadily increased in recent years, reaching the five-year relative survival rate at about 89% of the cases. However, not all patients benefited from those progresses, since the lack of effective treatments against metastasis is still the major hindrance to survival and quality of life of patients suffering from BC.

Although medicinal mushroom extracts have been proposed as promising anti-cancer agents, their precise impacts on metastatic breast cancer are still to be clarified. For this purpose, the present study exploited the effect of a novel medicinal mushroom blend, namely Micotherapy U-care, in a 4T1 triple-negative mouse breast cancer model.

Mice were orally administered with Micotherapy U-care, consisting of a mixture of:

  • Agaricus blazei,
  • Ophiocordyceps sinensis,
  • Ganoderma lucidum,
  • Grifola frondosa, and
  • Lentinula edodes.

The syngeneic tumor-bearing mice were generated by injecting 4T1 cells in both supplemented and non-supplemented mice. After sacrifice 35 days later, specific endpoints and pathological outcomes of the murine pulmonary tissue were evaluated.

Histopathological and ultrastructural analysis and (ii) immunohistochemical assessment of TGF-ß1, IL-6 and NOS2, COX2, SOD1 as markers of inflammation and oxidative stress were performed. The QoL was comparatively evaluated.

Micotherapy U-care supplementation, starting before 4T1 injection and lasting until the end of the experiment, dramatically reduced the pulmonary metastases density, also triggering a decrease of fibrotic response, and reducing IL-6, NOS, and COX2 expression. SOD1 and TGF-ß1 results were also discussed.

These findings support the valuable potential of Micotherapy U-care as adjuvant therapy in the critical management of triple-negative breast cancer.

Experimental flow chart (A) and schematic drawing highlighting the main outcomes (B).

In collaboration with:

Moj račun
Košarica

No products in the cart.

Treat yourself to a 5% discount for a mushroom dose of well-being and join the GOBA community!

For those who don’t just want quick fixes, but lasting balance. For those who understand that health is not a goal, but a way of life. For those who aren’t just looking for a nutritional supplement, but a companion on the path to well-being. Because sometimes the smallest things bring the biggest changes. A 5% discount awaits you on your first purchase – as a small thank you for your trust.